Body composition changes after switching from protease inhibitors to raltegravir
Authors:
- Adrian CurranACAdrian Curran
- Esteban MartinezEMEsteban Martinez
- Maria SaumoyMSMaria Saumoy
- Luis del RioLRLuis del Rio
- Manuel CrespoMCManuel Crespo
- Maria LarrousseMLMaria Larrousse
- Daniel PodzamczerDPDaniel Podzamczer
- Joaquin BurgosJBJoaquin Burgos
- Montse LoncaMLMontse Lonca
- Pere DomingoPDPere Domingo
- Jose Maria GatellJGJose Maria Gatell
- Esteban RiberaEREsteban Ribera
- 20 February 2012
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 26 (4) , 475-481
Abstract
To compare 48-week changes in body fat distribution and bone mineral density (BMD) between patients switching from a ritonavir-boosted protease inhibitor (PI/r) to raltegravir (RAL) and patients continuing with PI/r. Substudy of the prospective, randomized, open-label, multicenter SPIRAL study. Patients were randomized (1 : 1) to continue with the PI/r-based regimen or switch to RAL, maintaining the rest of the treatment unchanged. Dual-energy X-ray absorptiometry and computed tomography scans were performed at baseline and after 48 weeks to measure body fat and bone composition, analyzing intragroup and intergroup differences. Eighty-six patients were included and 74 patients (39 RAL, 35 PI/r) completed the substudy. Significant increases in median [interquartile range (IQR)] visceral adipose tissue (VAT) [20.7 (-2.4 to 45.6) cm(2), P = 0.002] and total adipose tissue (TAT) [21.4 (-1.3 to 55.4) cm(2), P = 0.013] were seen within the PI/r group. No significant changes in body fat were seen with RAL or between treatment groups. Regarding bone composition, total BMD [0.01 (0 to 0.02) g/cm(2), P = 0.002], total hip BMD [0.01 (0 to 0.03) g/cm(2), P = 0.015] and total hip T score [0.12 (-0.05 to 0.21) SD, P = 0.004] significantly increased with RAL, with no significant changes within the PI/r group. Differences between treatment groups were significant in femoral neck BMD [0.01 (-0.02 to 0.02) g/cm(2), P = 0.032] and T score [0.01 (-0.18 to 0.18) SD, P = 0.016]. Although there were no significant changes in body fat between groups, maintaining a PI/r-based regimen was associated with a significant increase in VAT and TAT. Switching to RAL led to a significant increase in femoral neck BMD when comparing between groups.Keywords
This publication has 26 references indexed in Scilit:
- Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224sClinical Infectious Diseases, 2011
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic AnalysesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentAIDS, 2009
- The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical ImplicationsToxicologic Pathology, 2009
- Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual NucleosidesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Mixed Patterns of Changes in Central and Peripheral Fat Following Initiation of Antiretroviral Therapy in a Randomized TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIVNew England Journal of Medicine, 2006
- Prevalence of, Evolution of, and Risk Factors for Fat Atrophy and Fat Deposition in a Cohort of HIV-Infected Men and WomenClinical Infectious Diseases, 2005
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infectionAIDS, 2000